Larkspur Biosciences Launches with $35.5 Million in Financing to Build the Next Precision Immunotherapies to Outsmart Cancer

Larkspur Biosciences, a biotechnology company building the next precision immunotherapies to outsmart cancer, launched today with $35.5 million in combined seed and Series A financing. Larkspur’s approach targets the unique ways that tumors hijack the immune system.